Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021 08:00 ET
|
Impel NeuroPharma
Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adults Mobilized 60-Person Salesforce with a Targeted...
Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
November 08, 2021 08:00 ET
|
Impel NeuroPharma
SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...
Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine
September 28, 2021 08:30 ET
|
Impel NeuroPharma
Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space ...
Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering
September 09, 2021 20:00 ET
|
Impel NeuroPharma
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from...
Impel NeuroPharma Announces Launch of Proposed Public Offering
September 07, 2021 16:01 ET
|
Impel NeuroPharma
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from...
Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine
September 03, 2021 08:50 ET
|
Impel NeuroPharma
TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich Upper Nasal SpaceTRUDHESA Is Well Tolerated and Delivers Rapid,...
Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 16, 2021 08:05 ET
|
Impel NeuroPharma
TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021 Preparations On Track for Potential TRUDHESA Launch...
Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
August 09, 2021 16:01 ET
|
Impel NeuroPharma
SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies...
Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal Headache
August 09, 2021 08:00 ET
|
Impel NeuroPharma
Study Shows TRUDHESA™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief Exploratory Patient-Reported Outcomes Data Indicated More Than One Third of Patients Experienced Pain Freedom...
Impel NeuroPharma to Present at the 2021 Wedbush Pacgrow Virtual Healthcare Conference
August 03, 2021 16:01 ET
|
Impel NeuroPharma
SEATTLE, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies...